Brachytherapy: A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.Iridium Radioisotopes: Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes.Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Radiotherapy Planning, Computer-Assisted: Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.Radiation Injuries: Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.Ruthenium Radioisotopes: Unstable isotopes of ruthenium that decay or disintegrate emitting radiation. Ru atoms with atomic weights 93-95, 97, 103, and 105-108 are radioactive ruthenium isotopes.Dose Fractionation: Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Radiometry: The measurement of radiation by photography, as in x-ray film and film badge, by Geiger-Mueller tube, and by SCINTILLATION COUNTING.Radiotherapy, Image-Guided: The use of pre-treatment imaging modalities to position the patient, delineate the target, and align the beam of radiation to achieve optimal accuracy and reduce radiation damage to surrounding non-target tissues.Vaginal Neoplasms: Tumors or cancer of the VAGINA.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Beta Particles: High energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.Iodine Radioisotopes: Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.Radiotherapy, Computer-Assisted: Computer systems or programs used in accurate computations for providing radiation dosage treatment to patients.Dose-Response Relationship, Radiation: The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Ytterbium: Ytterbium. An element of the rare earth family of metals. It has the atomic symbol Yb, atomic number 70, and atomic weight 173. Ytterbium has been used in lasers and as a portable x-ray source.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Radiotherapy: The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.Tongue Neoplasms: Tumors or cancer of the TONGUE.Choroid Neoplasms: Tumors of the choroid; most common intraocular tumors are malignant melanomas of the choroid. These usually occur after puberty and increase in incidence with advancing age. Most malignant melanomas of the uveal tract develop from benign melanomas (nevi).Fat Necrosis: A condition in which the death of adipose tissue results in neutral fats being split into fatty acids and glycerol.Radiation Dosage: The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).Rectum: The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL.Rectal Diseases: Pathological developments in the RECTUM region of the large intestine (INTESTINE, LARGE).Magnetic Resonance Imaging, Interventional: Minimally invasive procedures guided with the aid of magnetic resonance imaging to visualize tissue structures.Urinary Retention: Inability to empty the URINARY BLADDER with voiding (URINATION).Radiotherapy, Conformal: Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.Organs at Risk: Organs which might be damaged during exposure to a toxin or to some form of therapy. It most frequently refers to healthy organs located in the radiation field during radiation therapy.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Histiocytoma: A neoplasm containing HISTIOCYTES. Important forms include BENIGN FIBROUS HISTIOCYTOMA; and MALIGNANT FIBROUS HISTIOCYTOMA.Uveal Neoplasms: Tumors or cancer of the UVEA.Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.Strontium Radioisotopes: Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes.Radioisotopes: Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Prosthesis Implantation: Surgical insertion of a prosthesis.Radioisotope Teletherapy: A type of high-energy radiotherapy using a beam of gamma-radiation produced by a radioisotope source encapsulated within a teletherapy unit.Radiotherapy, High-Energy: Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.Glossectomy: Partial or total surgical excision of the tongue. (Dorland, 28th ed)Radiation Oncology: A subspecialty of medical oncology and radiology concerned with the radiotherapy of cancer.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Radiation ProtectionProstate-Specific Antigen: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Androgen Antagonists: Compounds which inhibit or antagonize the biosynthesis or actions of androgens.Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).Colon, Sigmoid: A segment of the COLON between the RECTUM and the descending colon.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Rhenium: Rhenium. A metal, atomic number 75, atomic weight 186.2, symbol Re. (Dorland, 28th ed)Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Phantoms, Imaging: Devices or objects in various imaging techniques used to visualize or enhance visualization by simulating conditions encountered in the procedure. Phantoms are used very often in procedures employing or measuring x-irradiation or radioactive material to evaluate performance. Phantoms often have properties similar to human tissue. Water demonstrates absorbing properties similar to normal tissue, hence water-filled phantoms are used to map radiation levels. Phantoms are used also as teaching aids to simulate real conditions with x-ray or ultrasonic machines. (From Iturralde, Dictionary and Handbook of Nuclear Medicine and Clinical Imaging, 1990)Mastectomy, Segmental: Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. (1/1081)

PURPOSE: To compare the prostate-specific antigen (PSA) relapse-free survival outcome and incidence of late toxicity for patients with early-stage prostate cancer treated at a single institution with either three-dimensional conformal radiotherapy (3D-CRT) or transperineal permanent implantation (TPI) with iodine-125 seeds. MATERIALS AND METHODS: Patients with favorable-risk prostate cancer, defined as a pretreatment PSA of less than or equal to 10.0 ng/mL, Gleason score of 6 or lower, and stage less than or equal to T2b, were selected for this analysis. Between 1989 and 1996, 137 such patients were treated with 3D-CRT and 145 with TPI. The median ages of the 3D-CRT and TPI groups were 68 years and 64 years, respectively. The median dose of 3D-CRT was 70.2 Gy, and the median implant dose was 150 Gy. Prostate-specific antigen relapse was defined according to the American Society of Therapeutic Radiation Oncology Consensus Statement, and toxicity was graded according to the Radiation Therapy Oncology Group morbidity scoring scale. The median follow-up times for the 3D-CRT and TPI groups were 36 and 24 months, respectively. RESULTS: Eleven patients (8%) in the 3D-CRT group and 12 patients (8%) in the TPI group developed a biochemical relapse. The 5-year PSA relapse-free survival rates for the 3D-CRT and the TPI groups were 88% and 82%, respectively (P = .09). Protracted grade 2 urinary symptoms were more prevalent among patients treated with TPI compared with 3D-CRT. Grade 2 urinary toxicity, which was manifest after the implant and persisted for more than 1 year after this procedure, was observed in 45 patients (31%) in the TPI group. In these 45 patients, the median duration of grade 2 urinary symptoms was 23 months (range, 12 to 70 months). On the other hand, acute grade 2 urinary symptoms resolved within 4 to 6 weeks after completion of 3D-CRT, and the 5-year actuarial likelihood of late grade 2 urinary toxicity for the 3D-CRT group was only 8%. The 5-year actuarial likelihood of developing a urethral stricture (grade 3 urinary toxicity) for the 3D-CRT and TPI groups was 2% and 12%, respectively (P<.0002). Of 45 patients who developed grade 2 or higher urinary toxicity after TPI, the likelihood of resolution or significant improvement of these symptoms at 36 months from onset was 59%. The 5-year likelihood of grade 2 late rectal toxicity for the 3D-CRT and TPI patients was similar (6% and 11%, respectively; P = .97). No patient in either group developed grade 3 or higher late rectal toxicity. The 5-year likelihood of posttreatment erectile dysfunction among patients who were initially potent before therapy was 43% for the 3D-CRT group and 53% for the TPI group (P = .52). CONCLUSION: Both 3D-CRT and TPI are associated with an excellent PSA outcome for patients with early-stage prostate cancer. Urinary toxicities are more prevalent for the TPI group and subsequently resolve or improve in most patients. In addition to evaluating long-term follow-up, future comparisons will require detailed quality-of-life assessments to further determine the impact of these toxicities on the overall well-being and quality of life of the individual patient.  (+info)

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. (2/1081)

BACKGROUND AND METHODS: We compared the effect of radiotherapy to a pelvic and para-aortic field with that of pelvic radiation and concurrent chemotherapy with fluorouracil and cisplatin in women with advanced cervical cancer. Between 1990 and 1997, 403 women with advanced cervical cancer confined to the pelvis (stages IIB through IVA or stage IB or IIa with a tumor diameter of at least 5 cm or involvement of pelvic lymph nodes) were randomly assigned to receive either 45 Gy of radiation to the pelvis and para-aortic lymph nodes or 45 Gy of radiation to the pelvis alone plus two cycles of fluorouracil and cisplatin (days 1 through 5 and days 22 through 26 of radiation). Patients were then to receive one or two applications of low-dose-rate intracavitary radiation, with a third cycle of chemotherapy planned for the second intracavitary procedure in the combined-therapy group. RESULTS: Of the 403 eligible patients, 193 in each group could be evaluated. The median duration of follow-up was 43 months. Estimated cumulative rates of survival at five years were 73 percent among patients treated with radiotherapy and chemotherapy and 58 percent among patients treated with radiotherapy alone (P=0.004). Cumulative rates of disease-free survival at five years were 67 percent among patients in the combined-therapy group and 40 percent among patients in the radiotherapy group (P<0.001). The rates of both distant metastases (P<0.001) and locoregional recurrences (P<0.001) were significantly higher among patients treated with radiotherapy alone. The seriousness of side effects was similar in the two groups, with a higher rate of reversible hematologic effects in the combined-therapy group. CONCLUSIONS: The addition of chemotherapy with fluorouracil and cisplatin to treatment with external-beam and intracavitary radiation significantly improved survival among women with locally advanced cervical cancer.  (+info)

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. (3/1081)

BACKGROUND AND METHODS: On behalf of the Gynecologic Oncology Group, we performed a randomized trial of radiotherapy in combination with three concurrent chemotherapy regimens -- cisplatin alone; cisplatin, fluorouracil, and hydroxyurea; and hydroxyurea alone -- in patients with locally advanced cervical cancer. Women with primary untreated invasive squamous-cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix of stage IIB, III, or IVA, without involvement of the para-aortic lymph nodes, were enrolled. The patients had to have a leukocyte count of at least 3000 per cubic millimeter, a platelet count of at least 100,000 per cubic millimeter, a serum creatinine level no higher than 2 mg per deciliter (177 micromol per liter), and adequate hepatic function. All patients received external-beam radiotherapy according to a strict protocol. Patients were randomly assigned to receive one of three chemotherapy regimens: 40 mg of cisplatin per square meter of body-surface area per week for six weeks (group 1); 50 mg of cisplatin per square meter on days 1 and 29, followed by 4 g of fluorouracil per square meter given as a 96-hour infusion on days 1 and 29, and 2 g of oral hydroxyurea per square meter twice weekly for six weeks (group 2); or 3 g of oral hydroxyurea per square meter twice weekly for six weeks (group 3). RESULTS: The analysis included 526 women. The median duration of follow-up was 35 months. Both groups that received cisplatin had a higher rate of progression-free survival than the group that received hydroxyurea alone (P<0.001 for both comparisons). The relative risks of progression of disease or death were 0.57 (95 percent confidence interval, 0.42 to 0.78) in group 1 and 0.55 (95 percent confidence interval, 0.40 to 0.75) in group 2, as compared with group 3. The overall survival rate was significantly higher in groups 1 and 2 than in group 3, with relative risks of death of 0.61 (95 percent confidence interval, 0.44 to 0.85) and 0.58 (95 percent confidence interval, 0.41 to 0.81), respectively. CONCLUSIONS: Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival among women with locally advanced cervical cancer.  (+info)

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. (4/1081)

BACKGROUND: Bulky stage IB cervical cancers have a poorer prognosis than smaller stage I cervical cancers. For the Gynecologic Oncology Group, we conducted a trial to determine whether weekly infusions of cisplatin during radiotherapy improve progression-free and overall survival among patients with bulky stage IB cervical cancer. METHODS: Women with bulky stage IB cervical cancers (tumor, > or =4 cm in diameter) were randomly assigned to receive radiotherapy alone or in combination with cisplatin (40 mg per square meter of body-surface area once a week for up to six doses; maximal weekly dose, 70 mg), followed in all patients by adjuvant hysterectomy. Women with evidence of lymphadenopathy on computed tomographic scanning or lymphangiography were ineligible unless histologic analysis showed that there was no lymph-node involvement. The cumulative dose of external pelvic and intracavitary radiation was 75 Gy to point A (cervical parametrium) and 55 Gy to point B (pelvic wall). Cisplatin was given during external radiotherapy, and adjuvant hysterectomy was performed three to six weeks later. RESULTS: The relative risks of progression of disease and death among the 183 women assigned to receive radiotherapy and chemotherapy with cisplatin, as compared with the 186 women assigned to receive radiotherapy alone, were 0.51 (95 percent confidence interval, 0.34 to 0.75) and 0.54 (95 percent confidence interval, 0.34 to 0.86), respectively. The rates of both progression-free survival (P<0.001) and overall survival (P=0.008) were significantly higher in the combined-therapy group at four years. In the combined-therapy group there were higher frequencies of transient grade 3 (moderate) and grade 4 (severe) adverse hematologic effects (21 percent, vs. 2 percent in the radiotherapy group) and adverse gastrointestinal effects (14 percent vs. 5 percent). CONCLUSIONS: Adding weekly infusions of cisplatin to pelvic radiotherapy followed by hysterectomy significantly reduced the risk of disease recurrence and death in women with bulky stage IB cervical cancers.  (+info)

The Denolin Lecture 1998. Towards measurement of coronary blood flow in patients and its alteration by interventions. (5/1081)

AIM: Several methods of measuring coronary blood flow in intact conscious man are reviewed, on the basis of personal contributions or the experiences of our teams. METHODS AND RESULTS: It is important to distinguish between global, regional and transmural blood flow measurements. The advantages and limitations of the following methods are discussed: diffusible inert and radioactive tracers, dye dilution, roentgendensitometry, magnetic resonance imaging and contrast echocardiography. In interventional cardiology it is most important to be able to measure flow through single coronary vessels. Information on coronary artery Doppler velocity during vasodilation and at rest is less useful than the concept of fractional flow reserve. This is based on pressure measurements under maximal vasodilation to ascertain the presence of borderline flow-limiting lesions. This information is necessary in order to decide whether to proceed with angioplasty or not. CONCLUSIONS: The historical design of percutaneous coronary angioplasty and beta-irradiation of coronary restenosis, established under the author's guidance, are put into perspective. The author pays tribute to many excellent colleagues who worked with him at the Zurich and Geneva University Hospitals.  (+info)

Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a phase I and drug incorporation study. (6/1081)

PURPOSE: Preclinical studies show a significant increase in the ratio of the radiosensitizer bromodeoxyuridine (BUdR) in tumors versus the intestinal mucosa during the drug elimination period, compared with the ratio during drug infusion. We constructed a phase I study in patients with locally advanced cervix cancer, using alternating cycles of BUdR and radiation therapy (RT). PATIENTS AND METHODS: Eighteen patients with stage IIB to IVA cervix cancer participated. A treatment cycle consisted of a 4-day BUdR infusion followed by a week of pelvic RT, 15 Gy twice daily in 1.5-Gy fractions. After three cycles, additional BUdR was infused, followed by brachytherapy. The fraction of thymidine replaced by BUdR and the fraction of cells incorporating BUdR were determined in rectal mucosa and tumor biopsies at the end of the first BUdR infusion (day 5), at the middle of the first RT week (day 10), and at the time of brachytherapy. RESULTS: Dose-limiting toxicity was observed in one of 16 patients receiving 1,000 mg/m2/d x 4 days and in both patients receiving 1,333 mg/m2/d x 4 days each cycle. After a median follow-up of 39 months, 12 patients (66%) were free of pelvic disease and nine (50%) were alive and disease free. The ratio of tumor to rectum BUdR incorporation averaged 1.5 to 1.8 and did not differ significantly between day 5 and day 10. A trend toward reduced ratio was observed at brachytherapy. Drug-containing cells in rectal biopsies migrated from the crypts to the mucosal surface. CONCLUSION: In this schedule, 1,000 mg/m2/d is the maximum-tolerated dose of BUdR. BUdR incorporation levels in tumors were consistent with clinically significant radiosensitization. The migration of BUdR-containing rectal mucosa cells from the crypts to the surface at the time of RT suggests that this regimen may offer a relative sparing of the mucosa from radiosensitization.  (+info)

Late coronary occlusion after intracoronary brachytherapy. (7/1081)

BACKGROUND: Intracoronary brachytherapy appears to be a promising technology to prevent restenosis. Presently, limited data are available regarding the late safety of this therapeutic modality. The aim of the study was to determine the incidence of late (>1 month) thrombosis after PTCA and radiotherapy. METHODS AND RESULTS: From April 1997 to March 1999, we successfully treated 108 patients with PTCA followed by intracoronary beta-radiation. Ninety-one patients have completed at least 2 months of clinical follow-up. Of these patients, 6.6% (6 patients) presented with sudden thrombotic events confirmed by angiography 2 to 15 months after intervention (2 balloon angioplasty and 4 stent). Some factors (overlapping stents, unhealed dissection) may have triggered the thrombosis process, but the timing of the event is extremely unusual. Therefore, the effect of radiation on delaying the healing process and maintaining a thrombogenic coronary surface is proposed as the most plausible mechanism to explain such late events. CONCLUSIONS: Late and sudden thrombosis after PTCA followed by intracoronary radiotherapy is a new phenomenon in interventional cardiology.  (+info)

Proliferative potential of malignant glioma cells before and after interstitial brachytherapy. (8/1081)

The viability of tumor cells in radionecrotic tissue after interstitial brachytherapy (BRTX) was evaluated using immunohistochemical markers of proliferative potential in primary and recurrent tumors. Tumor specimens from 30 patients with malignant gliomas (14 anaplastic astrocytomas, 16 glioblastomas) taken before and after BRTX were examined using MIB-1 monoclonal antibody. Histological examination of specimens obtained by craniotomy or stereotactic biopsy after BRTX revealed tumor recurrence in 18 patients and radionecrosis in 12 patients including two with pure radionecrosis and 10 with a mixture of both tumor and radionecrosis. The MIB-1 index of the tumors with radionecrosis was 7.6 +/- 5.5%, and that of the primary tumors was 17.0 +/- 11.2%, showing a significant difference (p < 0.05). There was no significant difference between the MIB-1 index of the primary tumors with local recurrence after BRTX and the primary tumors which underwent radionecrosis. Although morphologically viable tumor cells were found in the radionecrotic tissue, BRTX causes a reduction in the proliferative potential of these tumor cells.  (+info)

TOLEDO, OH - 5 Apr, 2017 - Bionix Radiation Therapy will be exhibiting at the 2017 American Brachytherapy Society Annual meeting in Boston, Massachusetts, from April 20-22, 2017.. Bionix will be featuring cutting edge precision balloon technology for esophageal, anal and rectal cancers. Bionix is excited to announce a new brachytherapy solution at the ABS Annual meeting, be sure to visit booth #310 to witness the unveiling of this new solution.. The event takes place at the Seaport Hotel in Boston, Massachusetts. Bionix will be showcasing their solutions for anal and rectal cancers, the AR-1TM, or anorectal applicator, a disposable brachytherapy applicator designed specifically for the treatment of anal and rectal cancers. Along with the E-AppTM, or esophageal applicator, a disposable brachytherapy applicator designed specifically for the treatment of upper GI cancers.. To learn more about the 2017 American Brachytherapy Society Annual Meeting, visit their Website at: ...
Thiagarajan, A., Lin, K., Lu, J.J., Tan, L.K.S., Loh, T.K.S., Goh, B.C., Lin, K., Tiong, C.E. (2006). Sequential external beam radiotherapy and high-dose-rate intracavitary brachytherapy in T1 and T2 nasopharyngeal carcinoma: An evaluation of long-term outcome. Laryngoscope 116 (6) : 938-943. [email protected] Repository. https://doi.org/10.1097/01.MLG.0000215173.14473. ...
Capital Regional Cancer Center also offers High-Dose Rate Brachytherapy (HDR) - an internal radiation therapy method that delivers a highly localized therapeutic dose of radiation directly to the tumor location. The radioactive source is applied using temporarily placed applicators. HDR involves a shortened treatment duration and is almost performed as an outpatient. As the therapy is extremely focused, the dose to surrounding organs and tissues is minimized, reducing potential side effects of treatment.. ...
Permanent prostate brachytherapy involves placing many radioactive seeds within the prostate to treat prostate cancer. During the procedure, an ultrasound probe is placed in the rectum to help guide the placement of seeds. The seeds emit radiation that dissipates over a few months.. ...
BEBIG - brachytherapy prostate cancer, brachytherapy for prostate cancer, microsources for brachytherapy treatment of prostate cancer
Lu, J.J., Shakespeare, T., Back, M., Mukherjee, R., Wynne, C.J., Goh, B.C., Tan, K.S.L., Tiong, C.E. (2004). Adjuvant High-Dose Rate Brachytherapy after Chemoradiation for Treatment of Early T-Stage Nasopharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials 27 (2) : 132-135. [email protected] Repository. https://doi.org/10.1097/01.coc.0000046592.90778. ...
It is with great enthusiasm and anticipation that we invite you to attend the 2017 American Brachytherapy Society (ABS) Annual Meeting. Our meeting theme is "the Value of Brachytherapy in Multidisciplinary Cancer Care" and the meeting will be held at the Boston World Trade Center in the historic city of Boston, from April 20 - 22. Dan Petereit and Ann Kopp our Scientific Program Chairs for the meeting, and together with the co-chairs is putting together a very enriching and stimulating program. A wide variety of national and international speakers have been invited to present their data and to debate controversial issues. We will again offer the Judith Stitt Best Abstract Awards that will be highlighted in a plenary session. The Resident Travel Awards will continue to encourage resident involvement in the society and we will again offer a Residents Luncheon at our meeting. The Seaport Hotel & World Trade Center is Located in the bustling Seaport District, one of Bostons most popular ...
Experiences of high dose rate brachytherapy: Hello, I was diagnosed 2 weeks ago. I have stage T2 with Gleason of 3+4, and psa of 10. Although it seems to be contained it appears to be close to the nerves surrounding the prostate which makes nerve sparing RP unlikely to succeed. I have been...
TY - JOUR. T1 - High-dose-rate brachytherapy using molds for lip and oral cavity tumors. AU - Unetsubo, Teruhisa. AU - Matsuzaki, Hidenobu. AU - Takemoto, Mitsuhiro. AU - Katsui, Kuniaki. AU - Hara, Marina. AU - Katayama, Norihisa. AU - Waki, Takahiro. AU - Kanazawa, Susumu. AU - Asaumi, Jun-Ichi. PY - 2015/4/8. Y1 - 2015/4/8. N2 - Background: High-dose-rate (HDR) brachytherapy using the mold technique is a less invasive treatment for early lip and oral cavity cancer. However, limited reports exist regarding the feasibility of this method. In this retrospective study, we evaluated the outcome of this therapy and investigated its feasibility for lip and oral cavity tumors. Methods: Between May 2002 and December 2010, 17 patients (median age, 80.0years) with histologically confirmed squamous cell carcinoma of the lip or oral cavity were treated by means of HDR brachytherapy using the mold technique after external beam radiotherapy (EBRT). Tumor sites included the buccal mucosa in eight cases, the ...
A noteworthy study recently published in JAMA® (The Journal of the American Medical Association) by a multi-institutional group of prostate cancer experts, concluded that men with high risk prostate cancer treated with external beam radiation therapy (EBRT), brachytherapy seed implant, and hormone deprivation therapy, were associated with significantly better prostate cancer-specific mortality rates (deaths caused by prostate cancer) compared to radical prostatectomy or EBRT with hormone deprivation therapy.2. Additionally, researchers from the British Columbia Cancer Agency, published a landmark, Level 1 evidence trial, that concluded men with Intermediate & High-Risk prostate cancer randomized to low-dose brachytherapy boost, EBRT, and hormone deprivation (versus men randomized to EBRT boost, EBRT and hormone deprivation therapy) were twice as likely to be free of biochemical failure (detectable and rising Prostate Specific Antigen (PSA)) at a median follow-up of 6.5 years.3. Peter Orio, DO, ...
1 Sung et al. Safety and efficacy of radioactive seed localization with I-125 prior to lumpectomy and/or excisional biopsy. European Journal of Radiology. 2013; 82. 1453-1457. 2 Chiu et al. Radioactive seed localization of non-palpable breast lesions in an academic comprehensive cancer program community hospital setting. The American Surgeon. 2014; 80: 675-679. 3 Diego et al. Localizing high risk lesions for excisional breast biopsy: a comparison between radioactive seed localization and wire localization. Annals of Surgical Oncology. 2014; 21: 3268-3272. 4 Barentsz et al. Radioactive seed localization for non-palpable breast cancer. British Journal of Surgery. 2013; 100: 582-588. 5 Murphy et al. Radioactive seed localization compared to wire localization in breast-conserving surgery: Initial 6-Month Experience. Annals of Surgical Oncology. 2013; 20: 4121-4127. 6 McGhan et al. Radioactive seed localization for non-palpable breast lesions: Review of 1,000 consecutive procedures at a single ...
ALSIO VIEJO, Calif. - Cianna Medical, maker of the SAVI® breast brachytherapy applicator, recently announced the launch of BEST Forum™, a new educational resource for physicians to obtain the latest findings and research in breast brachytherapy and gain insights into best practices and available technology.. Both online and in person, BEST Forum (www.theBESTForum.com) brings together world-renowned thought leaders in the field of breast cancer care to discuss their extensive experiences and research in brachytherapy, treatment and clinical outcomes.. Breast brachytherapy is a form of accelerated partial breast irradiation (APBI), a shortened course of radiation therapy for early-stage breast cancer patients following lumpectomy surgery.. At the BEST Forum website, which launched in early May, physicians can view presentations from brachytherapy experts, as well as download white papers, presentation slides and supporting clinical data, and register for future presentations.. "Were excited to ...
There has been much controversy over the past several years regarding the best treatment option for prostate cancer. To date, there is no clear-cut data to prove the advantage of surgery over other treatment options. Recently, there has been a new enthusiasm for IMRT (Intensity Modulated Radiation Therapy) and proton beam radiation therapy for the treatment of prostate cancer. Again, there is no data to support that either therapy is superior to brachytherapy for the treatment of prostate cancer. However, there is data suggesting that brachytherapy is superior to IMRT. Data from the latest Meeting of the American Brachytherapy Society, presented by Michael Zelefsky, M.D. from Sloan-Kettering Cancer Center, NY (June 2009), compared 2292 patients that were treated with IMRT or brachytherapy. Results found that the 7-year PSA relapse-free survival (PRFS) for low-risk patients was 92.4% for patients treated with brachytherapy and 91.6% for patients treated with IMRT. However, the 7-year PRFS for ...
Even though the women in the study were treated with brachytherapy before the ASTRO guidelines were developed, the results suggest that many women unsuitable for brachytherapy are getting brachytherapy. This possibility is more of a concern because brachytherapy use has continued to increase since 2007 when the last of the patients in this study were treated.. Findings from another large study suggest that brachytherapy may not be as effective as whole-breast radiation therapy at reducing recurrence risk. Women in that study who got brachytherapy after lumpectomy for early-stage breast cancer were nearly twice as likely to later have a mastectomy because of cancer recurrence compared to women who got traditional whole-breast radiation therapy. That study also found that treatment complications -- such as rib fracture, breakdown of fat in the breast (fat necrosis), breast pain, and inflammation in the lungs -- were more likely among women treated with brachytherapy. Some of these higher ...
The article outlines the approach to applying the mechatronic technologies and robotic systems in carrying out the brachytherapy operations. To calculate the elastic state of the flexible needles of different geometry in the prostate model, a mathematical model of the flexible needle deformation has been applied which took into account the medium reaction and was based on the theory of flexible and elastic rods. The numeric calculations for different types of needles have been introduced for the first time. Also for the first time the advantages of applying flexible needles for brachytherapy procedure have been mathematically justified.
Treatment of prostate cancer with interstitial brachytherapy (radioactive seeds implantation) (costs for program #49753) ✔ St. Antonius Hospital ✔ Department of Urology and Pediatric Urology ✔ BookingHealth.com
... has been successfully modified by scientists at Isotopen Technologie München AG (ITM), solving problems of radiation exposure to Rhenium-188. The researchers are now producing Rhenium-188 with previously unknown high specific activity in a new type of generator, Isotopen Technologie reports. |br /|, Endovascular brachytherapy has been successfully modified by scientists at Isotopen Technologie München AG (ITM), solving problems of radiation exposure to Rhenium-188. The researchers are now producing Rhenium-188 with previously unknown high specific activity in a new type of generator, Isotopen Technologie reports. |br /|
The Head and Neck Working Group of the GEC-ESTRO (Groupe Européen de Curiethérapie - European Society for Therapeutic Radiology and Oncology) published in 2009 the consensus recommendations for low-dose rate, pulsed-dose rate and high-dose rate brachytherapy in head & neck cancers. The use of brachytherapy in combination with external beam radiotherapy and/or surgery was also covered as well as the use of brachytherapy in previously irradiated patients. Given the developments in the field, these recommendations needed to be updated to reflect up-to-date knowledge.. The present update does not repeat basic knowledge which was published in the first recommendation but covers in a general part developments in (1) dose and fractionation, (2) aspects of treatment selection for brachytherapy alone versus combined BT+EBRT and (3) quality assurance issues.. Detailed expert committee opinion intends to help the clinical practice in lip-, oral cavity-, oropharynx-, nasopharynx-, and superficial cancers. ...
... Published by QYResearch at researchbeam.com . Global Brachytherapy Afterloaders, Brachytherapy Seeds Industry 2016 Deep Market Research Report is a research report by Key Manufacturers, Applications, Developments and Trends with covering regions China, US, Europe & Japan
Learn about brachytherapy seeds, is a basic part of brachytherapy treatments for cancer. Radiation can be delivered inside the body using a brachytherapy seed.
The co-incidence of synchronous intraepithelial neoplasia and early stage invasive lung cancer is not a rare phenomenon. The need for curative treatment and the invasive potential of squamous cell pulmonary carcinoma in situ have been a topic of controversy. Surgical resection still remains the treatment of choice. Varieties of endoscopic techniques such as brachytherapy were developed as an alternative to surgery in selected patients. External beam radiation therapy has been used traditionally in combination with endobronchial brachytherapy in the treatment of roentgenographically occult lung cancer, and can be offered for all patients, but is handicapped, because these tumors are radiographically invisible ...
TY - GEN. T1 - Trans-urethral ultrasound imaging of the prostate for applications in prostate brachytherapy. T2 - Analysis of phantom and in vivo data. AU - Holmes III, David R.. AU - Davis, B.. AU - Bruce, Charles J. AU - Wilson, T.. AU - Robb, R.. PY - 2001. Y1 - 2001. N2 - 3D Trans-Urethral Ultrasound (TUUS) imaging is a new imaging technique for the diagnosis and treatment of prostate disease. Our current research focuses on the potential of TUUS in therapy guidance during transperineal interstitial permanent prostate brachytherapy (TIPPB). TUUS may complement or potentially replace x-ray fluoroscopy and TRUS in providing data for determining the prostate boundary and radiation source locations. Prostate boundary detection and source localization using TUUS were tested on an ultrasound-equivalent prostate phantom and in a patient during TIPPB. Data collection was conducted with a 10 French, 10 MHz ultrasound catheter controlled by an Acuson Sequoia™ workstation. 2D and 3D TUUS scans were ...
ISO 21439:2009 specifies methods for the determination of absorbed-dose distributions in water or tissue that are required prior to initiating procedures for the application of beta radiation in ophthalmic tumour and intravascular brachytherapy]. Recommendations are given for beta-radiation source calibration, dosemetry measurements, dose calculation, dosemetric quality assurance, as well as for beta-radiation brachytherapy treatment planning. Guidance is also given for estimating the uncertainty of the absorbed dose to water. ISO 21439:2009 is applicable to "sealed" radioactive sources, such as plane and concave surface sources, source trains of single seeds, line sources, shell and volume sources, for which only the beta radiation emitted is of therapeutic relevance.. The standardization of procedures in clinical dosemetry described in ISO 21439:2009 serves as a basis for the reliable application of beta-radiation brachytherapy. The specific dosemetric methods described in ISO 21439:2009 apply ...
Purpose: Treatment of choroidal melanoma (CMM) with either iodine-125 (I125) plaque brachytherapy or enucleation yields similar survival outcomes. As such, we have used brachytherapy as primary treatment for large CMMs for more than a decade. Herein, we evaluate our cohort of patients with large CMM initially treated with plaque brachytherapy to determine rate of and factors associated with secondary enucleation.. Methods: A retrospective chart review of patients with large CMMs diagnosed and treated at our institution from January 1, 1988 to February 1 2013. Main outcome measures were need for secondary enucleation, local tumor recurrence, all cause mortality, development of metastases, initial apical tumor height and maximal basal diameter.. Results: 245 patients with large CMM were treated primarily with plaque brachytherapy. Local control was achieved in 230 patients (93.8%). Of the 15 patients (6.2%) with local recurrence, 8 underwent secondary enucleation and 7 deferred further treatment. ...
Within the recent resurgence of brachytherapy as treatment for prostate cancer, many new devices have been conceived in the preparation of surgical brachytherapy equipment. Specifically, this work encompasses the automated preparation of preloaded surgical brachytherapy applicators or "needles" through the loading of radioactive seed elements and benign spacer elements. While traditionally a manual operation, current device methodology in this application revolves around semi-automatic mechanical interaction within the element loading procedure. Mechanical interaction can subject elements to damage, specifically seed elements due to thin metallic construct. Damage to elements within a loading system can result in failure of the performed brachytherapy treatment causing potential harm to the patient. Hesitancy in acceptance of these mechanical separation element loading devices can be attributed to the failure nature of these devices. This work seeks to solve the current issue of element damage ...
Purpose The treatment planning (TP) in high-dose-rate (HDR) endobronchial brachytherapy (EB) can be based on various forms of imaging. In the case of lung cancer, one-dimensional or two-dimensional imaging is standard. The dose coverage of the target (planning target volume - PTV) and organs...
The UWADCL is capable of calibrating the following low energy brachytherapy sources, or applicable well chambers utilizing them. All sources are calibrated in units of air kerma strength (U). For I-125, Pd-103, and Ir-192, each source model is a separate calibration point. The Cs-137 calibration point will cover most tube-type sources in the medical community.. For dosimetry information regarding specific seed models, please click here to go to the AAPM/RPC Joint Registry of Low-energy Brachytherapy Seeds meeting the AAPM dosimetric prerequisites.. ...
Doctors can use brachytherapy alone or in addition to external-beam radiation therapy to provide a "boost" of radiation to a tumor while sparing surrounding normal tissue. Brachytherapy may be able to deliver higher doses of radiation to some cancers than external-beam radiation therapy while causing less damage to normal tissue.. Several brachytherapy techniques are used in cancer treatment, based on locations of cancer, dose and period of treatment. Interstitial brachytherapy uses a radiation source placed within tumor tissue, such as within a prostate tumor. Intracavitary brachytherapy uses a source placed within a surgical cavity or a body cavity, such as the chest cavity, near a tumor. Episcleral brachytherapy, which is used to treat melanoma inside the eye, uses a source that is attached to the eye.. In interstitial brachytherapy, radioactive isotopes are sealed in tiny pellets, the size of a grain of rice. These seeds are placed in the body using delivery devices, such as needles, ...
A growing instance of cancer across the globe is a primary factor boosting revenue growth of the global brachytherapy devices market. Market Research Reports Search Engine (MRRSE) has studied the global brachytherapy devices market in a new report titled Brachytherapy Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2022. The report focuses on the benefits of brachytherapy as a more effective therapy for the treatment of cancer that employs radiation in doses that are concentrated and localized to the cancer cells. Brachytherapy devices are popular as they facilitate efficient treatment in a relatively shorter time period with low side effects. This is a major growth driver for the global brachytherapy devices market. The report highlights the different drivers and factors likely to impact market growth over the forecast period.. Request for Sample Report: https://www.mrrse.com/sample/3509. The brachytherapy devices market is estimated to reach a ...
The options available for patients with recurrent prostate cancer are limited. Men who have failed external-beam irradiation as the primary treatment are rarely considered for potentially curative salvage therapy. Traditionally, only palliative treatments have been offered with hormonal intervention or simple observation. A significant percentage of these patients have only locally recurrent cancer and are thus candidates for curative salvage therapy. Permanent brachytherapy with iodine-125 or palladium-103 has been used in an attempt to eradicate the remaining prostate cancer and prevent the need for additional intervention. It is critical in this population to identify patients most likely to have distant metastases or who are unlikely to suffer death or morbidity from their recurrence, in order to avoid potential treatment morbidity in those unlikely to benefit from any intervention. Following salvage brachytherapy, up to 98% of these cancers may be locally controlled, and 5-year freedom from second
The dosimetry of sources used in interstitial brachytherapy has been the subject of considerable research in recent years. A number of articles have appeared (Appendix C) introducing revised calibration standards, source strength specification quantities, and dose calculation formalisms. Some of these articles advocate revision of basic dosimetry data, including dose rate constants, radial dose functions, and anisotropy functions for 192Ir, 125I, and 103Pd sources. In particular, the Interstitial Collaborative Working Group (ICWG), which was sponsored by the National Cancer Institute, has completed its final report. With all these reports appearing in the literature, the medical physics community is faced with a confusing situation regarding the selection of dosimetry data. Therefore, the Radiation Therapy Committee of the American Association of Physicists in Medicine (AAPM) in 1988 formed Task Group No. 43 to review the recent publications on the dosimetry of interstitial brachytherapy sources ...
Varian Medical Systems will be exhibiting its complete line of hardware, software, and applicators for HDR and LDR brachytherapy, including the VariSource iX, GammaMedplus iX and the GammaMedplus 3/24 iX HDR afterloaders, the BrachyVision treatment planning system plus the Vitesse module for using transrectal ultrasound (TRUS) images as the basis for a prostate cancer treatment plan. For LDR treatments, the VariSeed treatment planning system is a leading system for this highly specialized form of brachytherapy.. ...
Brachytherapy (the term is derived from the Greek word brachys, which means brief or short) refers to cancer treatment with ionizing radiation delivered via radioactive material placed a short distance from, or within, the tumor. In prostate cancer, brachytherapy involves the ultrasound- and template-guided insertion of radioactive seeds into...
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether external-beam radiation therapy is more effective with or without indinavir and ritonavir in treating patients with brain metastases.. PURPOSE: This randomized phase II trial is studying external-beam radiation therapy alone to see how well it works compared to external-beam radiation therapy given together with indinavir and ritonavir in treating patients with brain metastases. ...
ALISO VIEJO, Calif. - BioLucent, Inc. today announced the launch of its SAVI™ applicator. The SAVI device offers a multi-catheter, single-entry approach to breast brachytherapy as part of breast-conserving cancer treatment.. The product introduction occurs at the annual meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO), November 5-9 in Philadelphia. BioLucent will exhibit the new device at the companys Booth No. 1439.. The SAVI applicator is for use in accelerated partial breast irradiation (APBI) after lumpectomy. The applicator is a hybrid of two earlier APBI approaches, combining the tissue-sparing dosimetry of interstitial brachytherapy with the single-entry ease of intracavitary ("balloon") brachytherapy.. The SAVI applicators ability to deliver a precisely targeted dose of radiation is designed to give more flexibility in treatment planning to the radiation oncologist and physicist.. APBI was developed as an alternative to whole-breast irradiation. Both ...
A study by researchers at Brigham and Womens Hospital found that brachytherapy treatment was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis also revealed geographic disparities and decline in brachytherapy treatment in the United States.
The oncology centre at Netcare Pinehaven Hospital in Krugersdorp has considerably bolstered its cancer treatment options, with the introduction of high dose rate (HDR) brachytherapy, an internally delivered form of radiation therapy for the treatment of various kinds of cancers.. "HDR brachytherapy involves the application of a radioactive source in close proximity to malignant tumours in order to destroy them or reduce their size. Used to treat a range of cancers including cervical, uterus, endometrial, and oesophageal, the introduction of this technology at Netcare Pinehaven Hospital provides oncologists with an important tool in the fight against the disease," says Dr Cindy Aitton, head of Netcares Cancer Care division.. Dr Paul Paradza, one of the oncologists at the hospitals oncology centre, says HDR brachytherapy is highly effective, and can be used as a stand-alone treatment in suitable cases, or in conjunction with other cancer treatments such as chemotherapy, surgery and external beam ...
Apparatus, systems, and methods are provided for delivering brachytherapy into a target tissue region, e.g., a breast. In some embodiments, a flexible brachytherapy device is implanted that includes a therapy delivery portion having one or more radioactive sources securely retained thereto, and a tail portion extending from the therapy delivery portion. The brachytherapy device may be implanted in a helical configuration within the target tissue region. To assist in placement and removal of the brachytherapy device, a tubular sheath may be implanted by attaching (e.g., sliding over) a helically coiled needle that is advanced into the body by screw-like rotation. Once implanted, the sheath and the brachytherapy device may extend outside the body, where they may be folded and secured flat against the skin. The device and sheath may be removed at therapy completion.
For patients with advanced or recurrent gynecologic malignancies, interstitial brachytherapy (ISBT) has been shown to improve local control, while maintaining an acceptable toxicity profile [1]. Patients with complex and bulky disease are often indicated for the brachytherapy component to be delivered using a perineal template to guide the ISBT implant. Though treatment regimens vary, the application of the prescription dose is commonly delivered over three to six fractions from a single perineal implant that is sutured to the patient [1,2,3]. These fractions are delivered a minimum of six hours apart, with the total treatment time spanning multiple, consecutive days. To aid in the safe adoption of complex high-dose-rate (HDR) brachytherapy gynecologic treatments, consensus-based commissioning guidelines provide a standardized approach to minimize treatment errors [4]; however, the availability of institutional resources create differences in practical clinical implementation, which often ...
This study is the first to show that platelet activation is increased by the brachytherapy currently applied in clinical practice. A notable increase was found after brachytherapy compared with PCI without irradiation. We have previously identified increased platelet activation after conventional PCI as an independent risk factor for acute ischaemic events.20 The data on radiation delivery devices submitted for US Food and Drug Administration (FDA) approval showed that patients treated with radiation benefit from a reduction in recurrent stenosis but also have the disadvantage of an increased rate of thrombotic events.192324 Thrombotic occlusions are associated with increased mortality after PCI21 and an increased risk of myocardial infarctions after VBT.1419232526 The increase in platelet activation after brachytherapy is not suppressed by concomitant treatment with aspirin and clopidogrel. Both drugs were given to all 23 patients three to four weeks before elective brachytherapy. In the group ...
Oakland CA (PRWEB) September 17 2013 Dennis R. Hill MD has confirmed today that he will be speaking to the American Cancer Society Man-to-Man support group on High Dose Rate Brachytherapy Tuesday September 24 from 6:30 to 8:00pm at the Summit Campus of Alta Bat,Dennis,R.,Hill,,MD,to,Speak,at,the,American,Cancer,Society,Man-to-Man,Support,Group,to,Discuss,HDR,Brachytherapy,for,Prostate,Cancer,Treatment,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
Endobronchial brachytherapy in the treatment of malignant lung tumours.: A prospective study was made to assess the short-term clinical and endoscopic response
All information about the latest scientific publications of the Clínica Universidad de Navarra. High-dose-rate brachytherapy in lower eyelid cancer
Monotherapy with high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy are both recommended modalities for prostate cancer. The choice between HDR and LDR is dependent on patient, physician, and hospital preferences.
Brachytherapy in the treatment of cervical cancer: a review Robyn Banerjee,1 Mitchell Kamrava21Department of Radiation Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada; 2Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USAAbstract: Dramatic advances have been made in brachytherapy for cervical cancer. Radiation treatment planning has evolved from two-dimensional to three-dimensional, incorporating magnetic resonance imaging and/or computed tomography into the treatment paradigm. This allows for better delineation and coverage of the tumor, as well as improved avoidance of surrounding organs. Consequently, advanced brachytherapy can achieve very high rates of local control with a reduction in morbidity, compared with historic approaches. This review provides an overview of state-of-the-art gynecologic brachytherapy, with a focus on recent advances and their implications for women with cervical cancer.Keywords: cervical cancer, brachytherapy, image-guided
Radiation therapy might hurt men by inadvertently damaging their rectum. Men considering radiation therapy would be wise to ask their radiation oncologist about SpaceOar, a hydrogel product. SpaceOAR stands for Spacing Organs at Risk. Think of SpaceOar as a rectal spacer. Hydrogel is a water-like substance thats injected between the rectum and prostate in order to reduce the radiation dose to the rectum. Published studies have investigated its use with various kinds of radiation- IMRT, 3D-CRT, SBRT, protons, low dose rate brachytherapy, high dose rate brachytherapy, salvage radiation after primary prostatectomy, and salvage brachytherapy after primary radiation. Those studies say hydrogel is usually safe and adds about 12mm of space between the rectum and prostate. Very few men will feel the hydrogel - it is fully absorbed by your body within a year and then pissed out.. SpaceOar may have a very useful role in men with bowel inflammation, a history of rectal issues (hemorrhoids, for example), ...
Relevant Experience: CyberKnife Radiosurgery, Stereotactic Radiosurgery (SRS), Stereotactic Body Radiation Therapy (SBRT), Image-guided Radiation Therapy (IGRT), Intensity-Modulated Radiation Therapy (IMRT), Selective Internal Radiation Therapy (SIRT), High and Low-Dose Rate Brachytherapy for Prostate Cancer, Intracavitary High-Dose Rate Breast Brachytherapy, Intracavitary High-Dose Rate Brachytherapy for Gynecologic ...
Hdr brachytherapy for prostate cancer - Doctors Present Prostate HDR Brachytherapy in Barcelona. Prostacet provides a comprehensive blend of Vitamins, minerals and standardized herbal extracts designed to support healthy prostate function.
We wish to improve the swallowing function of patients with advanced cancer of the oesophagus, by carrying out a randomised clinical study in which we compare primary stenting followed by brachytherapy in the stent, 8 G x 3 with standard brachytherapy 8 Gy x 3.. The aim of the study is to investigate whether patients who receive a stent followed by brachytherapy have a better swallowing function without more pain at week +2,compared to patients who receive brachytherapy alone. ...
A brachytherapy device for the provision of brachytherapy is disclosed. The brachytherapy device has at least one source lumen located outside a movable surface of the device. The source lumen may be secured to the movable outer surface in a manner whereby relative movement of the source lumen relative to the movable outer surface is permitted. The brachytherapy device is inserted into a body cavity. After insertion, the movable surface is moved to position the at least one source lumen closer to the tissue boundary of the cavity. One or more sources of radiation are then placed within the at least one source lumen to provide a customizable treatment. Also disclosed are methods for providing brachytherapy via body cavities.
Other. Place An Inquiry Before Acquiring the report (Use Corporate Details Only):https://market.us/report/brachytherapy-afterloaders-market/#inquiry. The report answers important questions that companies may have when operating in the global brachytherapy afterloaders market. Some of the questions are given below:. - What will be the size of the global brachytherapy afterloaders market in 2029?. - What products have the highest growth rates?. - Which application is projected to gain a lions share of the global brachytherapy afterloaders market?. - Which region is foretold to create the most number of opportunities in the global brachytherapy afterloaders market?. - How will the market situation change over the next few years?. - What are the common business tactics adopted by players?. - What is the growth outlook of the global brachytherapy afterloaders market?. About Us:Market.us offers its clients a one-stop solution platform for all market research needs. Our focus on custom research, ...
Theragenics (NYSE:TGX) said today it picked up Eckert & Zieglers U.S. and Canadian brachytherapy seed business. Financial and other terms of the deal were not disclosed by the companies.. The transaction closed on the end of last year, and included U.S. and Candian customers and the rights to EZBs AnchorSeed, VariStrand and other seed products, as well as the rights to the SeedLock Needle.. "This transaction continues our long-standing commitment to prostate brachytherapy and the physicians and patients who depend on it. As a leading manufacturer and supplier in this market, our focus has always been on quality and service. Theragenics has a long history of providing physicians with the tools necessary to achieve outstanding results for their patients. We welcome the EZB customers and look forward to working with their programs. This transaction enhances our capabilities and expands our product portfolio for brachytherapy. Our legacy is improving lives and curing cancer. This transaction ...
The Prostate cancer guide aims to give the visitor in-depth information on prevention, management, brachytherapy and other treatments of the prostate cancer condition.
Hepel JT, Wazer DE. A comparison of brachytherapy techniques for partial breast irradiation. Brachytherapy. 2012;11(3):163-75. PMID: 21816686 www.ncbi.nlm.nih.gov/pubmed/21816686.. Holloway CL, OFarrell DA, Devlin PM, Stewart AJ. Brachytherapy. In: Gunderson LL, Tepper JE, eds. Clinical Radiation Oncology. 4th ed. Philadelphia, PA: Elsevier; 2016:chap 15.. National Cancer Institute. Breast cancer treatment (PDQ). Cancer.gov Web site. Updated August 11, 2016. www.cancer.gov/types/breast/hp/breast-treatment-pdq. Accessed September 13, 2016.. National Cancer Institute. Radiation therapy and you: support for people who have cancer. Cancer.gov Web site. www.cancer.gov/publications/patient-education/radiation-therapy-and-you. Accessed September 13, 2016.. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): breast cancer. Version 2.2016. www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed September 13, 2016. ...
Dr. Max Peters is a resident in Radiation Oncology based at the University Medical Center in Utrecht. His interest lies in MRI-guided LDR/HDR-focal therapy and focal salvage therapy for radiorecurrent prostate cancer. Dr. Peters will focus on salvage brachytherapy for local recurrence after EBRT/brachytherapy, explaining the indications for salvage brachytherapy and how patients are evaluated for treatment.. To register and confirm your attendance click here!. In addition to the above speakers I am pleased to announce that Dr. Pieter Dirix, a Radiation Oncologist at GZA in Antwerp, will be moderating the afternoon sessions. We look forward to seeing you on Saturday 27th January 2018 ...
A 19 year old man was involved in a motor vehicle accident and suffered multiple injuries including brain contusion and coma, multiple fractures in both legs, and chest contusion. He was initially admitted to the intensive care unit in another hospital and placed on mechanical ventilation for 4 weeks. Three months later he was referred to our pulmonary department with atelectasis of the right lung. Bronchoscopic examination revealed complete obstruction of the right main bronchus by membranous fibrotic tissue, thought to be secondary to a bronchial tear. The tear was probably just at the area of take off of the right upper lobe bronchus and therefore caused complete atelectasis of the right lung. Nd:Yag laser treatment was applied and the bronchus was completely reopened. Tissue obtained from the area of obstruction showed hyperplastic mucosa with granulation tissue. Subsequent bronchoscopies, however, revealed recurrent obstruction of the bronchus with partial collapse of the airway. A metal ...
Principal Investigator:INOUE Toshihiko, Project Period (FY):1995 - 1996, Research Category:Grant-in-Aid for Scientific Research (A), Section:一般, Research Field:Radiation science
The article by Drs. Merrick, Wallner, and Butler provides an excellent overview of issues pertaining to sexual dysfunction following prostate brachytherapy. The authors were the first to address the historical and current problems with diagnosing sexual dysfunction. They make a strong case for developing a quality-of-life (QOL) instrument that is specific for prostate brachytherapy. 1
Since publication of the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report in 1995 (TG-43), both the utilization of permanent source implantation and the number of low-energy interstitial brachytherapy source models commercially available have dramatically increased. In addition, the National Institute of Standards and Technology has introduced a new primary standard of air-kerma strength, and the brachytherapy dosimetry literature has grown sub- stantially, documenting both improved dosimetry methodologies and dosimetric characterization of particular source models. In response to these advances, the AAPM Low-energy Interstitial Brachy- therapy Dosimetry subcommittee (LIBD) herein presents an update of the TG-43 protocol for calculation of dose-rate distributions around photon-emitting brachytherapy sources. The updated protocol (TG-43U1) includes (a) a revised definition of air-kerma strength; (b) elimination of apparent activity for specification of source ...
Who does brachytherapy practice?. When performing brachytherapy, an experienced treatment team is needed, including a radiation oncologist, a medical physicist, a radiotherapy nurse, and in some cases a surgeon. Your doctor, who is a radiation oncologist, is the physician who evaluates the patient and determines the appropriate treatment. The medical physicist then makes detailed treatment calculations. Radiotherapy nurse informs the patient during the treatment and warns for possible side effects and helps to apply.. How will you feel during brachytherapy?. Brachytherapy is usually a painless procedure, with the application varying according to the shape. Gynecological practices can cause temporary pressure in the groin due to equipment placed in the vaginal cavity. If you see your doctor, you may be advised to take sedation or pain medication before starting the procedure, so an intravenous catheter can be placed in your arm or hand. You will need to be alone in the treatment room during the ...
Permanent seed brachytherapy involves implanting tiny radioactive seeds into your prostate gland. This is also called low dose rate brachytherapy. Radiation from the seeds destroys cancer cells in the prostate. You may have this treatment on its own or together with external beam radiotherapy or hormone therapy.
TY - JOUR. T1 - Outcomes of iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy. AU - Badiyan, Shahed N.. AU - Rao, Rajesh C.. AU - Apicelli, Anthony J.. AU - Acharya, Sahaja. AU - Verma, Vivek. AU - Garsa, Adam A.. AU - Dewees, Todd. AU - Speirs, Christina K.. AU - Garcia-Ramirez, Jose. AU - Esthappan, Jacqueline. AU - Grigsby, Perry W.. AU - William Harbour, J.. PY - 2014/3/15. Y1 - 2014/3/15. N2 - Purpose To assess the impact on local tumor control of intraoperative ultrasonographic plaque visualization and selective application of transpupillary thermotherapy (TTT) in the treatment of posterior uveal melanoma with iodine-125 (I-125) episcleral plaque brachytherapy (EPB). Methods and Materials Retrospective analysis of 526 patients treated with I-125 EPB for posterior uveal melanoma. Clinical features, dosimetric parameters, TTT treatments, and local tumor control outcomes were recorded. Statistical analysis was ...
BACKGROUND: Z4032 was a randomized study conducted by the American College of Surgeons Oncology Group comparing sublobar resection alone versus sublobar resection with brachytherapy for high-risk operable patients with non-small cell lung cancer (NSCLC). This evaluates early impact of adjuvant brachytherapy on pulmonary function tests, dyspnea, and perioperative (30-day) respiratory complications in this impaired patient population. METHODS: Eligible patients with stage I NSCLC tumors 3 cm or smaller were randomly allocated to undergo sublobar resection with (SRB group) or without (SR group) brachytherapy. Outcomes measured included the percentage predicted forced expiratory volume in 1 second (FEV1%), percentage predicted carbon monoxide diffusion capacity (DLCO%), and dyspnea score per the University of California San Diego Shortness of Breath Questionnaire. Pulmonary morbidity was assessed per the Common Terminology Criteria for Adverse Events version 3.0. Outcomes were measured at baseline and 3
High dose-rate brachytherapy is also known as HDR brachytherapy, or temporary brachytherapy. It is a type of internal radiotherapy. It involves inserting thin tubes into the prostate gland. A source of radiation is then passed down the tubes into the prostate for a few minutes to destroy cancer cells. The source of radiation is then removed, so no radiation is left in your body.
TY - JOUR. T1 - Treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy applicator for the delivery of accelerated partial breast irradiation. AU - Swanson, Todd. AU - Vicini, Frank A.. PY - 2008/6. Y1 - 2008/6. UR - http://www.scopus.com/inward/record.url?scp=73249130182&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=73249130182&partnerID=8YFLogxK. M3 - Article. AN - SCOPUS:73249130182. VL - 7. JO - American Journal of Oncology Review. JF - American Journal of Oncology Review. SN - 1542-9520. IS - 6. ER - ...
Prostate cancer patients who receive the optimum radiation dose on the same day as their brachytherapy implant may have a lower risk of relapse, according to a study conducted by researchers at the University Hospital of Navarre.
Purpose/Objectives: To report long-term efficacy and toxicity for a single-institution cohort of patients treated with low-dose-rate prostate brachytherapy permanent implant (PI) monotherapy. Methods and Materials: From 1996 to 2007, 1989 patients with low-risk (61.3%), intermediate-risk (29.8%), high-intermediate-risk (4.5%), and high-risk prostate cancer (4.4%) were treated with PI and followed up prospectively in a registry. All patients were treated with {sup 125}I monotherapy to 144 Gy. Late toxicity was coded retrospectively according to a modified Common Terminology Criteria for Adverse Events 4.0 scale. The rates of biochemical relapse-free survival (bRFS), distant metastasis-free survival (DMFS), overall survival (OS), and prostate cancer-specific mortality (PCSM) were calculated. We identified factors associated with late grade ≥3 genitourinary (GU) and gastrointestinal (GI) toxicity, bRFS, DMFS, OS, PCSM, and incontinence. Results: The median age of the patients was 67 years, and ...
In November of 2002, BCCA opened a randomized control phase II trial (accrued 41), which was further expanded to a randomized phase III trial in October 2004 (accrued 357) (ASCENDE RT), to compare the efficacy and toxicity of dose escalated radiating using EBRT vs. EBRT plus brachytherapy. Eligibility criteria included patients with ≤ Clinical stage (CS) T3a, any Gleason score (GS) and an initial PSA (iPSA) ≤40 ng/mL. All patients received 12 months ADT (8 months neoadjuvant) and elective pelvic nodal irradiation (46Gy/23 fractions 4 field conformal). Randomization was between high dose conformal EBRT (78Gy total dose to prostate) vs. a brachytherapy boost (115Gy, I125 Permanent Prostate Implant)(19). Trial was closed Dec 1, 2011. Results are pending publication. An interim analysis of ASCENDE-RT phases II-III (including all patients started on LHRH injections on or before Aug 31, 2006 N=161 pts) showed superior outcomes with combination of EBRT with brachytherapy boost as compared with an ...
The LumenCare Azure Applicator is specifically designed to improve delivery of lung cancer brachytherapy treatments and expands the treatable area.
Introduction: Among different kinds of oral cavity cancers, the frequency of tongue cancer occurrence is more significant. Brachytherapy is the most common method to cure tongue cancers. Long sources are used in different techniques of tongue brachytherapy. The objective of this study is to asses the dose distribution around long sources, comparing different radioisotopes as brachytherapy sources, measuring the homogeneity of delivered dose to treatment volume and also comparing mandible dose and dose of tongue in the regions near the mandible with and without using shield. Material and Method: The Monte Carlo code MCNP4C was used for simulation. The accuracy of simulation was verified by comparing the results with experimental data. The sources like Ir-192, Cs-137, Ra-226, Au-198, In-111 and Ba-131 were simulated and the position of sources was determined by Paris system. Results: The percentage of mandible dose reduction with use of 2 mm Pb shield for the sources mentioned above were: 35.4, ...
Introduction Dose calculation of tumor and surrounding tissues is essential during prostate brachytherapy. Three radioisotopes, namely, 125I, 103Pd, and 131Cs, are extensively used in this method. In this study, we aimed to calculate the received doses by the prostate and critical organs using the aforementioned radioactive seeds and to investigate the effect of scattering contribution for the legs on dose calculations. Materials and Methods The doses to organs of interest were calculated using MCNPX code and ORNL (Oak Ridge National Laboratory) phantom. Results Doses to the prostate as a source of radiation for 125I, 103Pd, and 131Cs were approximately 108.9, 97.7, and 81.5 Gy, respectively. Bladder, sigmoid colon, and testes received higher doses than other organs due to proximity to the prostate. Differences between the doses when tallying with the legs intact and with the legs voided were significant for testes, sigmoid colon contents, and sigmoid colon wall because of their proximity to the
Current data suggest that the clinical outcomes of patients treated with external beam radiotherapy (EBRT) and those of patients treated with permanent prostate brachytherapy are comparable if properl... more
Unlike other radiation modalities such as IMRT, IGRT and proton beam, prostate brachytherapy is immune to prostate motion.. There are many different technologies to treat prostate cancer with radiation, such as Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and proton beam therapy. These are all technologies that have been developed to promote and deliver the concept of dose escalation to the prostate; which means the more radiation you give to the prostate, the more likely you are to cure the cancer. However, there are adjacent structures to the prostate, which include the bladder and the rectum, and ideally, these structures should not receive any radiation. Thus, this limits the amount of radiation that can be delivered safely from the actual source. People have gone to great effort in order to account for prostate motion during treatment using external beam radiation sources, which they call "intrafractional motion". During the treatment time the ...
Brachytherapy, also called internal radiation or seed implants, is the placement of radioactive sources in or just next to a tumor. The radioactive sources may be left in place permanently or only temporarily, depending upon your cancer. To position the sources accurately, special catheters or applicators are used. Because the radiation sources are placed so close to the tumor, your doctors can deliver a large dose of radiation directly to the cancer cells with minimal exposure to normal tissue. The radioactive sources used in brachytherapy, such as thin wires, ribbons, capsules or seeds, come in small sealed containers. Some sources are placed permanently and are referred to as implants. These radioactive sources remain in the body after their radiation has been expended and the source is no longer radioactive. Other sources are placed temporarily inside the body, and the radioactive sources are removed after the prescribed dose of radiation has been delivered. There are two main types of ...
Brachytherapy, also called internal radiation or seed implants, is the placement of radioactive sources in or just next to a tumor. The radioactive sources may be left in place permanently or only temporarily, depending upon your cancer. To position the sources accurately, special catheters or applicators are used. Because the radiation sources are placed so close to the tumor, your doctors can deliver a large dose of radiation directly to the cancer cells with minimal exposure to normal tissue. The radioactive sources used in brachytherapy, such as thin wires, ribbons, capsules or seeds, come in small sealed containers. Some sources are placed permanently and are referred to as implants. These radioactive sources remain in the body after their radiation has been expended and the source is no longer radioactive. Other sources are placed temporarily inside the body, and the radioactive sources are removed after the prescribed dose of radiation has been delivered. There are two main types of ...
Introduction: Brachytherapy is one of the most common treatment modalities for gynecological cancer. The GZP6 brachytherapy system is one of the devices utilized in Iran. It has been considered particularly due to its low cost compared to other more complete and established systems. This system has some deficiencies including lack of a treatment planning software for non-predefined treatments, inability to change the gradually changeable dosimetric variables and using a point source estimation in dose calculation. This report presents a complementary treatment planning software (CTPS) to the systems own dedicated program. Material and Methods: First, the dosimetric characteristics of three GZP6 sources were calculated based on the TG-43 protocol using the MCNP4C Monte Carlo code. Then, the calculated dose distribution around the implanted applicators, based on the selected dwell positions and dwell times, was shown in a graphical user interface (GUI) written using the MATLAB software. Results: The
Urethral Spectroscopic Alarm (USA) Probe for Prostate Implants 1A.B. Rosenfeld, 1D.L. Cutajar, 1M.L.F. Lerch, 1G.J. Takacs, 2J.A. Bucci, 2L.J. Duggan, 3M. Zaider, 4M. Zelefsky and 3G.N. Cohen 1Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia, 2Institute for Prostate Cancer, St. George Cancer Care Centre, Kogarah, Australia, 3Department of Medical Physics and 4Department of Radiation Oncology, MSKCC, New York, NY Purpose: Prostate implants are associated with excellent biochemical outcome; however, their benefit in terms of overall survival remains unknown. For many patients with early, localized prostate cancer the decision to undergo a treatment of questionable benefit yet because of potentially significant morbidity - tangibly impacting upon their quality of life is understandably difficult. Thus, diminishing the risk of complications, whilst at the same time maintaining good dosimetric coverage of the tumor, remains the overriding concern in prostate brachytherapy
Brachytherapy (from Greek brachy meaning "short") is a treatment method that involves radiation of tumours using the radiation energy of an isotope placed inside or next to the tumour. Brachytherapy is an established technique in oncology which has been used for many years in our Centre. Many artificial radioactive isotopes are now being applied in cancer therapy with steadily improving physical properties to ensure safety for both patients and physicians. This allows a significant reduction in radiation damage to healthy tissues that surround the tumour.. Owing to the implementation of new-generation therapeutic machines, Microselectron HDR and PDR systems, the Greater Poland Cancer Centre has greatly increased the number of patients and cancer types treated to the level comparable with renowned centres in the European Union.. Every year, we provide treatment to over 1,000 patients who account for approx. 20% of all patients treated with radiotherapy. The Brachytherapy Unit is the only public ...
Today I finished my third and last brachytherapy. I found out about dilators here and during the second visit, I talked to the nurse about it. She filled out some papers for the doctor, but didnt give anything to me. The radiologist will see me in a month. So, I have no dilators and Im afraid a month is too long to start the ball rolling for this? At the very least, maybe I should have them already.. They used a medium size device for the brachytherapy and although I wasnt uncomfortable during insertion, I keep on thinking that the device didnt look too wide. So Im afraid of vaginal stenosis big time. How long after brachytherapy did you start dilation? Should I call the office/hospital back and ask for it, or do you think I can wait the four weeks till the next appointment? ...
The Nuclear and Energy Research Institute has produced, since 1998, iridium-192 wires used in low dose rate brachytherapy. In the paper the authors studied the influence of wire profile on the homogeneity distribution of radioactivity of iridium-192 along the wire. The authors propose the improvements in the quality control procedure that will provide more accurate measurement data and suggest changes in control devices. ...
Powerful brachytherapy treatments for brain, head & neck, esophageal, lung, breast, abdominal wall, ocular melanoma, gynecologic and prostate cancer.
The modern prostate brachytherapy procedure is characterized by ultrasound guidance, template assistance, and a return to a "closed" transperineal approach. This review traces the introduction and evolution of these elements and charts the development of the procedure from the ashes of previous, failed efforts. ...
Prostate brachytherapy guided by transrectal ultrasound is a common treatment option for early stage prostate cancer. Prostate cancer accounts for 28% of cancer cases and 11% of cancer deaths in men with 217,730 estimated new cases and 32,050 estimated deaths in 2010 in the United States alone. The major current limitation is the inability to reliably localize implanted radiation seeds spatially in relation to the prostate. Multimodality approaches that incorporate X-ray for seed localization have been proposed, but they require both accurate tracking of the imaging device and segmentation of the seeds. Some use image-based radiographic fiducials to track the X-ray device, but manual intervention is needed to select proper regions of interest for segmenting both the tracking fiducial and the seeds to evaluate the segmentation results, and to correct the segmentations in the case of segmentation failure, thus requiring a significant amount of extra time in the operating room. In this paper, we ...
Breast brachytherapy is an alternative to traditional EBRT for women who choose breast conservation rather than a mastectomy. Breast conservation therapy involves removing the tumor in a procedure called a lumpectomy, and is followed by radiation therapy to reduce the likelihood of recurrence. Traditional EBRT following a lumpectomy consists of five to six weeks of radiation treatment, five days per week. With breast brachytherapy, a site-specific, prescribed dose of radiation is administered during a five-day course of therapy. Because of the relatively short duration of the treatment course, breast brachytherapy is an attractive option for women who choose lumpectomy over mastectomy, but do not wish to undergo 6 weeks of EBRT.. The procedure for breast brachytherapy involves inserting a deflated balloon into the cavity where the tumor was removed. An applicator shaft, or catheter, connects the balloon to the outside of the breast. The balloon is filled with saline, and both the balloon and the ...
Patients treated with BT or RP have similar QOL scores. QOL after BT is worse in the first year after treatment, but thereafter it is better than QOL after RP.
SeeDos provide Prostate Brachytherapy and an extensive range of Radiotherapy, Ultrasound, Biopsy and Urology Equipment throughout the UK.
An interstitial brachytherapy apparatus and method for delivering and monitoring radioactive emissions delivered to tissue surrounding a resected tissue cavity. The brachytherapy device including a catheter body member having a proximal end, a distal end, and an outer spatial volume disposed proximate to the distal end of the body member. A radiation source is disposed in the outer spatial volume and a treatment feedback sensor is provided on the device. In use, the treatment feedback sensor can measure the radiation dose delivered from the radiation source.
This handbook provides a clinically relevant, succinct, and comprehensive overview of image-guided brachytherapy. Throughout the last decade, the utility of image guidance in brachytherapy has increased to enhance procedural development, treatment planning, and radiation delivery in an effort to optimize safety and clinical outcomes. Organized into two parts ...
September is National Prostate Cancer Awareness month, and what better timing for the release of two independent studies boosting the effectiveness of brachytherapy (radiation seed implants) as a modality for prostate cancer treatment. The two studies were done by The Prostate Cancer Foundation of Chicago and The Taussig Cancer Center at Cleveland Clinic. Is brachytherapy the best treatment for prostate cancer? Thats still up for debate. It is important to note that the studies were done in comparison to surgery (prostatectomy) and not to external beam radiation. In fact, the researchers at The Taussig Cancer Center said that brachytherapy was equally successful as external beam radiation for treatment of low-risk patients. Therefore, there is still no clear consensus on choosing brachytherapy over external beam radiation (i.e. IMRT technique) and vice-versa. However, considering brachytherapy and external beam radiation are equally successful techniques for early prostate cancer survival, as ...
Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.
Jilin has yet to be found in a new network in Jilin offered a reward for the radioactive source lost containers containing radioactive isotope container during transport has not yet been found as of press time lost 23 evening looking for lost radioactive source containers in Jilin Province, Songyuan municipal government announced that the Daqing drilling logging company of a container containing radioactive isotopes lost at present, the municipal government and relevant departments promptly launched the emergency response, Jilin Province Environmental Protection Bureau sent experts investigation group to Songyuan, the public security authorities are looking for organizations. As of the end of 24, Beijing Youth Daily reporter on the evening of 11 press time, with a radioactive isotope container has not yet been found. According to the notification issued by the Songyuan municipal government, from September 19, 2016 to 21, the Daqing drilling logging company in the construction of the transport ...
Historically, the approach of pre-operative radiation therapy with a combination of external beam radiation and low dose-rate (LDR) brachytherapy to doses of 60-70 Gy prescribed to point A was a standard approach in patients with endometrial cancer and significant co-morbidities. 10 More recently, there has been implementation of high dose rate (HDR) brachytherapy, 3D image-based planning, and intensity-modulated radiotherapy. In a study by Vargo et al, 11 the investigators evaluated patients with endometrial cancer who also had clinical involvement of the cervix with neoadjuvant external beam radiotherapy (45-50.4 Gy in 25-28 fractions) and image-based HDR brachytherapy (5-5.5 Gy times 3-4 fractions) plus chemotherapy followed by extra-fascial hysterectomy performed at a median of 6 weeks after radiotherapy. The authors found that at the time of surgery 91% of patients had no clinical cervical involvement, 58% had no pathological cervical involvement, and 24% had a complete pathologic response. ...
External Beam Radiation Therapy (EBRT) delivers radiation from outside the body with a machine called a linear accelerator. External Beam Radiation Therapy can be used as the only modality of treatment or in combination with chemotherapy, immunotherapy, or hormonal therapy, and can also be used prior to or following surgery, depending on the diagnosis and stage of disease. Although there can be side effects that develop gradually, the treatment itself is painless and relatively rapid.
PURPOSE: To evaluate the feasibility and the early toxicity of focal brachytherapy in highly selected localized prostate cancer patients.. METHODS AND MATERIALS: Twenty-one patients underwent a focal brachytherapy between February 2010 and March 2012, representing 3.7% of the cases treated by our group during this period. Patient selection was based on (at least) two series of prostate biopsies and a high-resolution MRI. Only patients with very limited and localized tumors, according to strict criteria, were selected for the procedure. The technique used a real-time procedure with the implantation of free 125I seeds and dynamic dose calculation. The prescribed dose for the focal volume was 145Gy.. RESULTS: The treated volume corresponded to a mean value of 34% of the total prostatic volume (range, 20-48%). For the focal volume, the mean D90 and V100 was 183.2Gy (range, 176-188Gy) and 99.3% (range, 98.8-100%), respectively. The technique was performed in an hour and a half. When compared with a ...
The causes of restless legs syndrome: Clinical presen - a is inaudible, no viagra dosierung tropfen quimbo splitting is heard. Indications for dialysis all indications are similar to the structures of the brush and smear the glass slide. Ume, urinating at night, sometimes hormone adh of central lipomas show hyperintense foci due to the rest of his lar contraction follows: First the atria, then the transversus abdominis m. Transversus abdominis m, arteriovenous stulas, common in dialysis patients, also produce continuous murmurs that origi. Eral to the neck of bilateral epididymitis see chapte, walter s, wolf h, barlebo h, jansen h. Urinary incontinence in patients undergoing transrectal ultrasoundguided permanent prostate brachytherapy, ebrt external beam radiation introduction the commonest side effect, with a history of systemic risk factors for nicantly affect the outcome of hour pad test if quantification of urinary bladder cance adv uro dash, a role for determining gen. Area, and behind an ...
imaging uses short (,0.1ms) bursts of ultrasound to induce small but measurable (2-20 microns) displacements in tissue. The response of the tissue to this impulsive excitation is determined by material properties. By measuring this response we produce images with contrast not present in ordinary ultrasound images (B-scans).. Magnetically induced vibration of brachytherapy seeds, combined with ultrasonic motion tracking, allows us to produce high contrast images of brachytherapy seeds embedded in tissue. Brachytherapy seeds are ordinarily difficult to image with ultrasound, and their accurate placement is necessary for effective therapy. Our magnetically induced motion imaging (MIMI) technique could serve as an enabling technology for real-time treatment planning of prostate brachytherapy.. ...
There is a strong rationale for the use of accelerated partial-breast irradiation: The large majority of in-breast recurrences are at or near the primary site, limiting the radiation dose to the primary site has the potential to decrease side effects, and treatment can be delivered over a shorter period (typically about 1 week). Accelerated partial-breast irradiation can be performed by a variety of techniques, including external-beam (conformal or intensity-modulated) radiation therapy, interstitial multicatheter brachytherapy, intracavitary brachytherapy, or intraoperative radiation, typically at the time of resection of the primary tumor.. In the United States, external-beam radiotherapy is the most frequent technique for accelerated partial-breast irradiation. Most U.S. radiation oncologists are not skilled in the use of interstitial brachytherapy.. The 5-year results of the European GEC-ESTRO trial comparing accelerated partial-breast irradiation and whole-breast irradiation have been ...
TY - JOUR. T1 - Early wound complications in advanced head and neck cancer treated with surgery and Ir192 brachytherapy. AU - Smith, Richard V.. AU - Krevitt, Lane. AU - Yi, Su Min. AU - Beitler, Jonathan J.. PY - 2000/1. Y1 - 2000/1. N2 - Objectives: Brachytherapy, either as primary or adjuvant therapy, is increasingly used to treat head and neck cancer. Reports of complications from the use of brachytherapy as adjuvant therapy to surgical excision have been limited and primarily follow Iodine 125 (I125) therapy. Early complications include wound breakdown, infection, flap failure, and sepsis, and late complications may include osteoradionecrosis, bone marrow suppression, or carotid injuries. The authors sought to identify the early wound complications that follow adjuvant interstitial brachytherapy with iridium 192 (Ir192). Study Design: A retrospective chart review of all patients receiving adjuvant brachytherapy at a tertiary medical center over a 4-year period. Methods: Nine patients ...
Brachytherapy is a treatment for cancer where radioactive sources are placed in or directly next to the tumor. The radioactive sources may be left in place permanently or only temporarily, depending upon the location of the tumor. The advantage of brachytherapy is that the radiation dose is delivered directly to the tumor while very little radiation is absorbed by nearby healthy tissues.. The Department of Radiation Oncology at University Hospital offers the most experienced physicians and physicists in the field of brachytherapy in Central New York. This expertise combined with procedures not offered in nearby regions, provides the patient with the most treatment options. Common sites implanted using brachytherapy at University Hospital are prostate, head and neck, cervix, endometrium, lung, brain, breast, abdomen and eye. ...
The study aimed to assess the suitability of linear array metal oxide semiconductor field effect transistor detectors (MOSFETs) as in vivo dosimeters to measure rectal dose in high dose rate brachythe
PlacidWay Medical Tourism provides best medical centers for Brachytherapy Internal Radiation Therapy, Cancer Treatment in Salzburg, Germany to patients from around the world. Explore affordable treatment options globally.
Prostate cancer diagnosis and brachytherapy, andrology - Peyronies disease, erectile dysfunction, prostate assessment and treatment, microsurgical vasectomy reversal, no-scalpel vasectomy, laser - holmium/thulium prostate surgery - HoLEP ...
TY - JOUR. T1 - Management of malignant airway obstruction. T2 - Clinical and dosimetric considerations using an iridium-192 afterloading technique in conjunction with the neodymium-YAG laser. AU - Schray, Mark F.. AU - McDougall, John C.. AU - Martinez, Alvaro. AU - Edmundson, Gregory K.. AU - Cortese, Denis. PY - 1985. Y1 - 1985. N2 - Fourteen patients with malignant airway obstruction have had 21 placements of a flexible nylon catheter for afterloading Iridium-192 using the flexible fiberoptic bronchoscope. Prescribed therapy was completed in 13 patients (18 courses). All patients had prior full-dose external irradiation, and no effective surgical or chemotherapeutic options remained. While many have had a trial of neodymium-YAG (yttrium-aluminum-garnet) laser therapy alone, eight patients received laser treatment one to three weeks prior to planned brachytherapy to provide immediate relief of symptoms and/or facilitate access and safe catheter placement. Most patients (64%) had recurrent ...
The present study, unlike previous 28-day studies in the porcine coronary model of restenosis, failed to demonstrate a significant reduction in neointimal formation for low-activity (0.5 to 1.0 μCi 32P) radioactive stents at 6 months in atherosclerotic pig coronary arteries.3 4 The lack of efficacy at 6 months in this model for the low-activity 32P stents suggests inadequate cumulative radiation dose, dose rate, or delayed neointimal growth after 28 days, although the higher injury score observed in the 0.5- to 1.0-μCi 32P group suggests that stent-induced arterial trauma may have contributed to the failure at this activity. Importantly, a dose-dependent increase in neointimal formation was observed with increasing activity of 32P on the stent at the time of implantation.. The histological features of the 3.0- to 12.0-μCi 32P radioactive stents observed in the present study are consistent with radiation-induced arteriopathy.9 10 11 Experimental studies in canine and rabbit models indicate ...
U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT03111069) titled Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children on April 6. Brief Summary: The goal of this clinical research study is to find the highest tolerable dose of heated doxorubicin that can be given to patients during surgery with abdominal tumors. The safety of this drug will also be studied. Study Start Date: Study Type: Interventional Condition: Malignant Neoplasms of Mesothelial and Soft Tissue Rhabdomyosarcoma, Pelvic Rhabdomyosarcoma, Abdominal Intervention: Procedure: Abdominal Surgery Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease). Unresectable Intra-Abdominal/Pelvic Tumors Group: ...
Intraoperative radiation therapy, or IORT, is the application of therapeutic levels of radiation to the tumor bed while the area is exposed during surgery. IORT is typically a component in the multidisciplinary treatment of locally advanced and recurrent cancer, in combination with external beam radiation, surgery and chemotherapy. As a growing trend in recent years, IORT can also be used in earlier stage cancers such as prostate and breast cancer. IORT was found to be useful and feasible in the multidisciplinary management of many solid tumors but further studies are needed to determine the benefit more precisely. Single-institution experiences have suggested a role of IORT e.g. in brain tumors and cerebral metastases, locally advanced and recurrent rectal cancer, skin cancer, retroperitoneal sarcoma, pancreatic cancer and selected gynaecologic and genitourinary malignancies. For local recurrences, irradiation with IORT is, besides brachytherapy, the only radiotherapeutic option if repeated ...
Definition of beta radiation in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is beta radiation? Meaning of beta radiation as a finance term. What does beta radiation mean in finance?
Contact x-ray brachytherapy[edit]. Contact x-ray brachytherapy (also called "CXB", "electronic brachytherapy" or the "Papillon ... Brachytherapy is delivered by placing radiation source(s) inside or next to the area requiring treatment. Brachytherapy is ... 2007). "Radiobiological concepts for brachytherapy". In Devlin P. Brachytherapy. Applications and Techniques. Philadelphia: LWW ... The GEC ESTRO handbook of brachytherapy. Belgium: ACCO.. *^ a b Gerbaulet A, et al. (2005). "General aspects". In Gerbaulet A, ...
Contact x-ray brachytherapy[edit]. Contact x-ray brachytherapy (also called "CXB", "electronic brachytherapy" or the "Papillon ... Brachytherapy is delivered by placing radiation source(s) inside or next to the area requiring treatment. Brachytherapy is ... 2007). "Radiobiological concepts for brachytherapy". In Devlin P (ed.). Brachytherapy. Applications and Techniques. ... Brachytherapy, in which a radioactive source is placed inside or next to the area requiring treatment, is another form of ...
by brachytherapy. *quackery type: electromagnetic therapy (alternative medicine). *by mechanical: manual therapy as ...
... -170 is gaining popularity as an X-ray source for cancer treatment via brachytherapy. This isotope has a half-life of ... Development of New Tm-170 Radioactive Seeds for Brachytherapy, Department of Biomedical Engineering, Ben-Gurion University of ... Brachytherapy. 10 (6): 461-465. doi:10.1016/j.brachy.2011.01.012. PMID 21397569. Ayoub, Amal Hwaree et al. ... "Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources ...
It can then be imaged by CT or MRI so that targeted brachytherapy can be tailored to the lesion as the malignancy evolves. Smit ... MRI-based target delineation for cervical cancer treatment within a rapid workflow environment for image-guided brachytherapy: ... A practical approach for centers without in-room MRI". Brachytherapy. 14 (6): 905-9. doi:10.1016/j.brachy.2015.07.005. PMID ...
Cesaretti, JA; Sheu, R-D; Yeh-Chi, L; Stoch, RG; Jenkins, AL (2008). "A novel technique of intracavitary 125I Brachytherapy for ... vertebral body metastases". Brachytherapy. 7 (2): 164-5. doi:10.1016/j.brachy.2008.02.224. Singh, H; Meyer, SA; Hecht, A; ...
"Howard Kelly establishes gynecologic brachytherapy in the United States". Brachytherapy. 9 (2): 178-184. doi:10.1016/j.brachy. ...
Merrick GS, Wallner K, Butler WM, Lief JH, Sutlief S (October 2001). "Short-term sexual function after prostate brachytherapy ...
... brachytherapy; 2011) Marcial, GG (2007-08-06). "Why Elekta May Be A Stockholm Standout". BusinessWeek. Retrieved 2016-07-28. ...
"Axxent Electronic Brachytherapy". Swedish Covenant Hospital. Retrieved 2011-03-21. "ICAD INC - FORM 10-Q ...", company U.S. ... Swedish Covenant Hospital in Chicago offered Xoft's Axxent Electronic Brachytherapy System treatment, beginning in 2008. The ... "iCAD to acquire electronic brachytherapy specialist Xoft" (press release), medicalphysicsweb.org, December 17, 2010. Jarzemsky ... the Axxent Electronic Brachytherapy System, was found to have left test subjects "riddled ... with hundreds of tiny particles ...
Journal of Contemporary Brachytherapy. 6: 297-299. doi:10.5114/jcb.2014.45133. PMC 4200180 . PMID 25337133. Sredniawa, ...
Brachytherapy service is also available. Radiology Department: This is the state of the art diagnostic department well equipped ...
... brachytherapy'. Among his early work were experiments in dark vision to determine why reading fluoroscopes was so challenging ...
The Hazy Dawn of Brachytherapy. Radiotherapy and Oncology (49) 1998 223-232 Voil, Charles H. Radium Production. Science 17 ...
Harmony Search Optimization for HDR Prostate Brachytherapy. ProQuest. 2008. k-d tree is another efficient range query data ...
Vision Reporter (9 April 2016). "Mulago's new brachytherapy system improves cancer treatment". New Vision. Kampala. Retrieved 9 ... brachytherapy system from Elekta. The system is part of a two-year renovation plan that UCI is implementing at a cost of US$49 ...
"A 10-year experience of pediatric brachytherapy". International Journal of Radiation Oncology, Biology, Physics. 32 (2): 451- ...
Radioactive iodine brachytherapy at the margins of wedge excision may reduce the risk of recurrence. Rarely, removal of a whole ... If cancer growth blocks a short section of bronchus, brachytherapy (localized radiotherapy) may be given directly inside the ... Reveiz, L; Rueda, JR; Cardona, AF (12 December 2012). "Palliative endobronchial brachytherapy for non-small cell lung cancer". ... Compared to external beam radiotherapy, brachytherapy allows a reduction in treatment time and reduced radiation exposure to ...
In brachytherapy planning involves selecting the appropriate catheter positions and source dwell times (in HDR brachytherapy) ... Brachytherapy planning Image-guided radiation therapy Thariat, Juliette; Hannoun-Levi, Jean-Michel; Sun Myint, Arthur; Vuong, ... Optimization of Catheter Position and Dwell Time in Prostate HDR Brachytherapy using HIPO and Linear Programming. World ... or seed positions (in LDR brachytherapy). The more formal optimization process is typically referred to as forward planning and ...
The Axxent Electronic Brachytherapy has not been recalled. Hoag Heart & Vascular Institute offers advanced surgical techniques ... In the media: The hospital's Axxent FlexiShield Mini study-treatment adjunct to the Axxent Electronic Brachytherapy breast ...
The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. ... Brachytherapy. 2014 Jan-Feb;13(1):1-14. doi: 10.1016/j.brachy.2013.11.008. Epub 2013 Dec 24. 40. Mulay K, Aggarwal E, Jariwala ... High dose rate interstitial brachytherapy in carcinoma eyelid: can it be a primary treatment modality? J Cancer Res Ther. 2011 ... American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: [email protected]; ABS - OOTF ...
These include brachytherapy, biopsy, neuroscience research and tumor removal. One type of tumor removal that would greatly ...
Small lesions can be treated with iodine-125 plaque brachytherapy. Distant metastases and mortality are rare. Mortality may ... "Management of medulloepithelioma of the ciliary body with brachytherapy". American Journal of Ophthalmology. 133 (6): 841-843. ...
Margaret Cleaves (1848-1917), pioneering doctor in the brachytherapy; M.D. 1873. Rebecca Lee Crumpler, (8 February 1831 - 9 ...
Brachytherapy and EBRT can also be used, singly or in combination, when there is a contraindication for hysterectomy. Both ... It can be delivered through vaginal brachytherapy (VBT), which is becoming the preferred route due to its reduced toxicity, or ... external beam radiotherapy (EBRT). Brachytherapy involves placing a radiation source in the organ affected; in the case of ...
The other radioisotopes of iodine are never used in brachytherapy. The use of 131I as a medical isotope has been blamed for a ... and in brachytherapy treatment (isotope confined in small seed-like metal capsules), where the low-energy gamma radiation ...
Our meeting theme is "the Value of Brachytherapy in Multidisciplinary Cancer Care" and the meeting will be held at the Boston ... It is with great enthusiasm and anticipation that we invite you to attend the 2017 American Brachytherapy Society (ABS) Annual ... We invite you to participate in an incredible worldwide gathering of leaders in the field of brachytherapy. ...
Prostate Brachytherapy Seed implants, also known as Low-dose-rate brachytherapy (LDR-BT) is a highly effective minimally ... Know Your Options: Prostate Brachytherapy is one of the most effective treatment options for prostate cancer. ... Brachytherapy Applications. Prostate Seeds. Scholarship & Fellowship Programs. Related Web Site Links. Sponsors. Corporate ... The American Brachytherapy Society finds many men diagnosed with Prostate Cancer are not presented with a highly effective ...
Permanent prostate brachytherapy. Permanent prostate brachytherapy involves placing many radioactive seeds within the prostate ...
Adjuvant High-Dose Rate Brachytherapy after Chemoradiation for Treatment of Early T-Stage Nasopharyngeal Carcinoma. ... Adjuvant High-Dose Rate Brachytherapy after Chemoradiation for Treatment of Early T-Stage Nasopharyngeal Carcinoma. American ...
Capital Regional Cancer Center also offers High-Dose Rate Brachytherapy (HDR) - an internal radiation therapy method that ...
High-dose-rate brachytherapy using molds for lip and oral cavity tumors. In: Radiation Oncology. 2015 ; Vol. 10, No. 1. ... High-dose-rate brachytherapy using molds for lip and oral cavity tumors. / Unetsubo, Teruhisa; Matsuzaki, Hidenobu; Takemoto, ... The total HDR brachytherapy dose was 24Gy. Prior to EBRT, two patients with neck metastasis underwent neck dissection, and one ... The total HDR brachytherapy dose was 24Gy. Prior to EBRT, two patients with neck metastasis underwent neck dissection, and one ...
Bionix® Radiation Therapy Exhibiting at the 2017 American Brachytherapy Society (ABS) Annual Meeting. Print This Article Share ... Bionix® Radiation Therapy Exhibiting at the 2017 American Brachytherapy Society (ABS) Annual Meeting. Back To Homepage ... Bionix is excited to announce a new brachytherapy solution at the ABS Annual meeting, be sure to visit booth #310 to witness ... TOLEDO, OH - 5 Apr, 2017 - Bionix Radiation Therapy will be exhibiting at the 2017 American Brachytherapy Society Annual ...
Experiences of high dose rate brachytherapy: Hello, I was diagnosed 2 weeks ago. I have stage T2 with Gleason of 3+4, and psa ... HDR brachytherapy or definitive RT (IMRT or proton therapy). Only HDR brachytherapy as monotherapy is still in experimental ... HDR brachytherapy or definitive RT (IMRT or proton therapy). Only HDR brachytherapy as monotherapy is still in experimental ... Low dose rate (LDR) brachytherapy with I-131 seeds is more suitable for low risk patients. For people with intermediate and ...
... brachytherapy for prostate cancer, microsources for brachytherapy treatment of prostate cancer ... American Brachytherapy Society, Association of brachytherapists of Russia "Low-dose-rate brachytherapy treatment of prostate ... The opinions of experts about brachytherapy. Zyryanov Alexander MD, Professor, Head of the Department of Oncology, State ... member of the American Brachytherapy Society Brachytherapy is the unique method that combines innovative technologies, ...
Brachytherapy pioneer Haakon Ragde, MD, chosen as ASTRO 2016 Honorary Member. Tue, Jun 28, 2016 22:25 CET. The American Society ...
Brachytherapy is a procedure to implant radioactive seeds (pellets) into the prostate gland to kill prostate cancer cells. The ... Types of brachytherapy:. *Low-dose rate brachytherapy is the most common type of treatment. The seeds stay inside your prostate ... Brachytherapy is often used for men with prostate cancer that is found early and is slow-growing. Brachytherapy has fewer ... Brachytherapy takes 30 minutes or more, depending on the type of therapy you have. Before the procedure, you will be given ...
Brachytherapy is a form of internal radiation therapy that uses ionizing radiation to kill cancer cells and shrink tumors. It ... Where is brachytherapy used?. Brachytherapy is mainly used to treat cancer of the prostate, cervix and womb but may also be ... Brachytherapy may be given on a permanent or temporary basis.. In permanent brachytherapy, seeds containing the radioactive ... For temporary brachytherapy, a catheter or applicator is used to deliver the radiotherapy to a target site. In cases of low ...
After brachytherapy, 63% of patients were assigned to observation, but 61 patients (37%) underwent hysterectomy a median of 10 ... The incidence of this was much higher in patients who had undergone hysterectomy than in those treated with brachytherapy alone ... Although she herself performs image-guided brachytherapy, this would be a new approach for many physicians in the United States ... "IGABT is the future of brachytherapy in cervical cancer," said Renaud Mazeron, MD, assistant professor at the Institut Gustave ...
Brachytherapy for breast cancer involves placing radioactive material in the area where breast cancer has been removed from the ... brachytherapy; APBI - brachytherapy; Accelerated partial breast irradiation - brachytherapy; Partial breast radiation therapy ... Electronic balloon brachytherapy; EBB; Intracavitary brachytherapy; IBB; Interstitial brachytherapy; IMB ... Brachytherapy may be given as low dose or high dose:. *Those receiving low-dose treatment are kept in the hospital in a private ...
Brachytherapy is radiation treatment that is given inside the patient, as close to the cancer as possible. The radiation is ... Brachytherapy. Facebook Twitter Linkedin Pinterest Print. What is brachytherapy?. Brachytherapy is radiation treatment that is ... Permanent brachytherapy. This is also called low-dose rate brachytherapy. Permanent brachytherapy uses implants called pellets ... How does brachytherapy work?. Brachytherapy can be given in 3 ways:. * Intracavitary treatment. The implants are placed inside ...
The largest study to date of the use of brachytherapy in penile cancer showed high rates of survival and allowed men to avoid ... "The use of brachytherapy in this very rare cancer type not only translated into high survival rates of men with this disease ... "This suggests that brachytherapy is an adequate up-front, organ-sparing strategy, which is usually associated with only mild to ... Low-dose-rate or pulse-dose-rate interstitial brachytherapy was used at a median dose of 65 Gy (range, 36.5 - 76 Gy). ...
The brachytherapy device has at least one source lumen located outside a movable surface of the device. The source lumen may be ... The brachytherapy device is inserted into a body cavity. After insertion, the movable surface is moved to position the at least ... Also disclosed are methods for providing brachytherapy via body cavities. ... A brachytherapy device for the provision of brachytherapy is disclosed. ...
... is a precise and targeted treatment of various cancers such as prostate, breast, skin and surface, rectum and ... Brachytherapy. Elekta Brachytherapy solutions are designed for precise, targeted treatment of various cancers such as prostate ... Brachytherapy Applicators. Fully integrated brachytherapy applicators. With a broad portfolio of specialized applicators, ... Celebrating 40 years of brachytherapy innovation. Elekta has been a pioneer in brachytherapy since 1975. Over the years, many ...
Brachytherapy has the advantage of delivering a high dose to the tumor while sparing the surrounding normal tissues. With ... Nag S, Tippin D (2003) Brachytherapy for pediatric tumors. Brachytherapy 2:131-138PubMedCrossRefGoogle Scholar ... Nag S, Kelly JF, Horton JL, Komaki R, Nori D (2001a) The American Brachytherapy Society recommendations for HDR brachytherapy ... Li S, Frassica D, DeWeese T (2003) A real-time image-guided intraoperative high-dose-rate brachytherapy system. Brachytherapy 2 ...
Y. Yu, T. Podder, Y. Zhang et al., "Robot-assisted prostate brachytherapy," in Proceedings of the 9th International Conference ... R. Nath, L. L. Anderson, J. A. Meli, A. J. Olch, J. A. Stitt, and J. F. Williamson, "Code of practice for brachytherapy physics ... In contemporary brachytherapy procedure, needle placement at desired location is challenging due to a variety of reasons. We ... During brachytherapy needle insertion forces deform the prostate tissue and displace the targeted seed positions [5]. The ...
Brachytherapy is radiation treatment that is given inside the patient, as close to the cancer as possible. The radiation is ... Permanent brachytherapy. This is also called low-dose rate brachytherapy. Permanent brachytherapy uses implants called pellets ... How does brachytherapy work?. Brachytherapy can be given in 3 ways:. * Intracavitary treatment. The implants are placed inside ... What is brachytherapy?. Brachytherapy is radiation treatment that is given directly into your body. It is placed as close to ...
Background There is limited information about survival effect of vaginal brachytherapy (VBT) and its comparison to external ... Sorbe B, Nordstrom B, Maenpaa J, Kuhelj J, Kuhelj D, Okkan S et al (2009) Intravaginal brachytherapy in FIGO stage I low-risk ... DuBeshter B, Estler K, Altobelli K, McDonald S, Glantz C, Angel C (2004) High-dose rate brachytherapy for Stage I/II papillary ... McCloskey SA, Tchabo NE, Malhotra HK, Odunsi K, Rodabaugh K, Singhal P et al (2010) Adjuvant vaginal brachytherapy alone for ...
Brachytherapy, which has proven to be a highly successful treatment for cancers of the prostate, cervix, endometrium, breast, ... Active in the brachytherapy market since 1994, Varian produces a full range of brachytherapy products including afterloaders, ... Image guided brachytherapy (IGBT) combines advanced imaging techniques with advanced brachytherapy procedures allowing doctors ... Other brachytherapy techniques include Pulse Dose Rate (PDR) and Image Guided Brachytherapy (IGBT). ...
i had brachy therapy for 3 straight weeks, monday to friday. holding in all the water required prior to undergoing the 15 ... Feb 2011 - Brachytherapy - Iodine 125. 3 mth 3.83 - 6 mth 3.18 - 9 mth 1.78 - 12 mth 2.77 - 17 mth 2.31 - 24 mth 3.73 - 27 mth ... Brachytherapy 12/9/08. 73 Iodine-125 seeds. Everything continues to function normally. PSA: 6 mo: 1.4, 1 yr: 1.0, 2 yr: .8, 3 ... Brachytherapy is where the radiation is implanted inside the prostate. It is usually done in one procedure. External beam ...
Brachytherapy. A procedure in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into ...
  • Methods: Between May 2002 and December 2010, 17 patients (median age, 80.0years) with histologically confirmed squamous cell carcinoma of the lip or oral cavity were treated by means of HDR brachytherapy using the mold technique after external beam radiotherapy (EBRT). (elsevier.com)
  • Only a radiation oncologist who specializes in the delivery of brachytherapy should be the one to tell a patient whether they are a candidate for prostate brachytherapy, and patients must feel empowered to seek the opinion of an experienced brachytherapist when deciding on the care they want to receive. (americanbrachytherapy.org)
  • Conclusions: Although there is a need to improve the technical aspects of the treatment protocol, HDR brachytherapy using the mold technique might be a therapeutic option for superficial lip or oral cavity tumors, especially in older patients who have a poor performance status or are in poor physical condition. (elsevier.com)
more